Genomill Health
- Company typePrivate
- Founded2016
- HeadquartersTurku, Finland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Genomill Health firmographics
Firmographics- Name
- Genomill Health
- Legal name
- Genomill Health Oy
- Website
- https://genomill.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Genomill Health industry classification
Industry- Product category
- Molecular Diagnostics - NGS Library Preparation
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Genomill Health is headquartered
LocationHeadquarters
- HQ city
- Turku
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
Genomill Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Technology Out-licensing: Genomill offers out-licensing opportunities for its Geno1® technologies (Bridge Capture™ and Nicking Loop™) to clinical laboratories, diagnostic companies, and other biotechnology companies. Licensing covers the use of proprietary protocols, probe design methods, and workflows for targeted NGS in liquid biopsy and other applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Targeted sequencing (Tx) application — low sequencing depth |
| Unit Pricing | Pay-as-you-go | Sample preparation (per sample) |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Genomill Health product offering
Product offeringCore offering
Genomill Health develops and out-licenses the Geno1® technology platform, featuring proprietary Bridge Capture™ and Nicking Loop™ technologies, which enable rapid, sensitive, and cost-efficient targeted next-generation sequencing (NGS) for oncology liquid biopsy and broader sequencing applications. The platform is platform-agnostic, compatible with all major NGS systems (Illumina, Ion Torrent, Oxford Nanopore, DNBSEQ, Element Aviti, PacBio Onso), and supports clinical labs and diagnostic companies in decentralized cancer genomics testing.
Product overview
Genomill Health offers a unified Geno1® technology platform comprising two core products: Bridge Capture™ and Nicking Loop™. Bridge Capture™ is a patented laboratory workflow for targeted DNA sequencing that converts samples into circular ssDNA libraries through probe-bridge complex circularization. Nicking Loop™ enables PCR-free amplification of circular DNA libraries for platform-agnostic sequencing readout. Together, these technologies power oncology applications (treatment selection, MRD detection, early detection) and sequencing applications (whole genome, exome, methylation, fragmentomics). The portfolio includes a modular pan-cancer panel with 887 probes targeting 123 genes and 24,236 mutations.
Differentiator
Problem solved
Functional benefit
Brands
- Geno1®: Core technology platform encompassing Bridge Capture™ and Nicking Loop™ for targeted DNA sequencing and diagnostics
- Bridge Capture™
- Nicking Loop™
Products and services
- Geno1® Technology Platform
Quantifiable outcome
- Over 50% cost reduction in NGS sample preparation compared to established methods
- +6 more outcomes
Companies that use Genomill Health
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Genomill Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature6 records
Genomill Health partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Cache DNAminorGenomill is evaluating Cache DNA's demo kits for DNA data storage applications. The collaboration explores using DNA not only as a storage medium but also as an active platform for information processing, combining Genomill's circular DNA libraries with Cache DNA's DNA storage system for dual-purpose DNA applications.
- iCAN (Finnish Digital Precision Cancer Medicine Flagship)coreGenomill and iCAN, the Finnish national cancer research flagship project, signed a partnership to improve detection of trace tumor DNA from thousands of biobank samples. Genomill brings its Geno1® platform to the collaboration; iCAN provides access to an extensive repository of patient samples and deep molecular profiling data from more than 10,000 patients. The partnership focuses on Minimal Residual Disease (MRD) and treatment selection applications, initially in colorectal and lung cancer.
- University of TurkucoreAcademic research collaboration with the University of Turku in Finland as part of the development and benchmarking of Bridge Capture technology, contributing scientific expertise and research infrastructure.
- TYKS Turku University HospitalcoreClinical research collaboration with TYKS Turku University Hospital in Finland for liquid biopsy technology validation, providing clinical samples and expertise for technology benchmarking.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Genomill Health competitors and assessment
Company assessmentBroad incumbents
- Agilent Technologies: Agilent's SureSelect target enrichment is a market-leading NGS sample-prep product used in clinical and research labs. It competes for the same customer wallet share as Bridge Capture in hybrid-capture workflows.
- New England Biolabs (NEB): NEB supplies enzymes and reagents for NGS library preparation across the industry, and is a competitor in the workflow chemistry space that Genomill's Geno1 platform serves.
- Integrated DNA Technologies (IDT): IDT (Danaher) provides NGS library prep reagents and probe-based target enrichment widely used by clinical labs. Their xGen panels compete head-to-head with Bridge Capture's modular, scalable design.
- Qiagen: Qiagen provides sample-prep technologies, QIAseq NGS panels, and molecular diagnostic solutions used by clinical and research labs. Its broad portfolio overlaps with Geno1's library prep and oncology panel offerings.
- Illumina: Illumina dominates the sequencing platform market and offers AmpliSeq (also benchmarked against Bridge Capture) and other sample-prep solutions. Genomill's technology is platform-agnostic but Illumina's Constellation initiative represents a potential adjacent technology.
- Roche / Foundation Medicine: Roche/Foundation Medicine offers comprehensive genomic profiling and liquid biopsy (FoundationOne Liquid CDx). Genomill's board advisor Mike Doherty is a former Foundation Medicine executive, reflecting direct industry relevance.
Direct peers
- Twist Bioscience: Twist Bioscience provides DNA synthesis and NGS target enrichment panels, directly competing with Bridge Capture's targeted sequencing offering. Both supply research and clinical NGS customers with custom panel content.
- Guardant Health: Guardant Health is a leading liquid biopsy company offering NGS-based cancer testing for treatment selection and MRD. It represents the established clinical end-to-end competitor in the same oncology applications Genomill is enabling.
- Personalis: Personalis offers NGS-based liquid biopsy and immuno-oncology assays, including tumor-informed MRD. It competes with Genomill in the treatment selection and MRD use cases the Bridge Capture pan-cancer panel targets.
- ArcherDx (Invitae): ArcherDx's LIQUIDPlex liquid biopsy NGS panels are explicitly benchmarked against Bridge Capture in Genomill's own published comparisons, making it a direct technology and product competitor in clinical liquid biopsy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Genomill Health social profiles
Digital presenceGenomill Health compliance and trust
Trust signalCompliance1 record
Genomill Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomill Health leadership team
Management profileNumber of profiles
Profiles10 records
Genomill Health funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomill Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomill Health
What does Genomill Health do?
Genomill Health develops and out-licenses the Geno1® technology platform, featuring proprietary Bridge Capture™ and Nicking Loop™ technologies, which enable rapid, sensitive, and cost-efficient targeted next-generation sequencing (NGS) for oncology liquid biopsy and broader sequencing applications. The platform is platform-agnostic, compatible with all major NGS systems (Illumina, Ion Torrent, Oxford Nanopore, DNBSEQ, Element Aviti, PacBio Onso), and supports clinical labs and diagnostic companies in decentralized cancer genomics testing.
Is Genomill Health a public or private company?
Genomill Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genomill Health founded?
Genomill Health was founded in 2016. It employs 1 to 10 people.
Where is Genomill Health based?
Genomill Health is headquartered in Turku, Finland, in the Europe region.
How does Genomill Health make money?
One revenue line is on record: technology Out-licensing.
Who are Genomill Health's main competitors?
Broad incumbents on record are Agilent Technologies, New England Biolabs (NEB), Integrated DNA Technologies (IDT), Qiagen, Illumina and Roche / Foundation Medicine. Direct peers are Twist Bioscience, Guardant Health, Personalis and ArcherDx (Invitae).
Does Genomill Health have an API?
No public API is recorded for Genomill Health.
What industry is Genomill Health in?
Genomill Health's product category is Molecular Diagnostics - NGS Library Preparation. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 2835.